Warm Autoimmune Hemolytic Anemia (WAIHA) Market is segmented By Treatment Modalities (Corticosteroids, Immunosuppressive medications, Splenectomy, Int....
Market Size in USD
CAGR5.3%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.3% |
Market Concentration | Medium |
Major Players | Novartis, Johnson & Johnson Innovative Medicine, Apellis Pharmaceuticals, Sanofi, Incyte Corporation |
The Warm Autoimmune Hemolytic Anemia (WAIHA) Market is estimated to be valued at USD 4.72 Billion in 2024 and is expected to reach USD 7.26 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031. WAIHA is a rare disease where the body's immune system abnormally destroys its own red blood cells. The growing cases of autoimmune diseases and increasing research funding for developing innovative treatment options are fueling the growth of this market.
The market has been witnessing positive trends with growing focus on developing targeted treatment options such as monoclonal antibodies. The emerging pipeline drugs with novel mechanisms of action hold promise to address unmet needs and drive the market growth during the forecast period. Additionally, advancement in understanding the pathophysiology of the disease and development of sensitive diagnostic techniques is estimated to contribute to the commercialization of new treatment paradigms.